Gewinn- und Verlustrechnung von TransMedics Group, Inc.

On October 01, 2026, TransMedics Group Inc (TMDX) shares fell 5.8%, closing at $78.64. The stock's performance over the past year has been challenging, with a 5

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Sept. 26, 2026Shareholders are encouraged to contact the

Shareholders are encouraged to contact the firm to discuss their rights and options at no costor obligation. We would handle any matter on a contingent fee basis, whereby you would notbe responsible for out-of-pocket payment of our legal fees or expenses.

TransMedics Group, Inc. (NASDAQ: TMDX - Get Free Report) shares shot up 4.5% during mid-day trading on Tuesday after an insider bought additional shares in the company. The stock traded as high as $89.15 and last traded at $89.7060. 308,922 shares traded hands during trading, a decline of 70% from the average daily volume of 1,029,492

These companies' sell-offs may have gone too far.

TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”), announces that K

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) (“TransMedics” or the “Company”).TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System, or.

ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.